Shares of Gilead Sciences Inc. GILD rose 1.60% to $107.62 Thursday, on what proved to be an all-around great trading session ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to ...

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

The Israeli strategist Yehoshafat Harkabi once observed that in military doctrine, the enemy is a target to destroy, but in ...

Before Gilead’s rise, the world in The Handmaid’s Tale was already falling apart. Food shortage, political unrest, environmental disasters — it was all there, bubbling just under the surface.

A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...